Aim: To evaluate relevance of clinical and molecular factors in adult low-grade gliomas (LGG) and to correlate with survival. Methods: We reviewed records from adult LGG patients from 1991 to 2015 who received surgery and had sufficient tissue to molecular biomarkers characterization. Results: 213 consecutive LGG patients were included: 17.4% were low-risk, according to Radiation Therapy Oncology Group (RTOG) risk assessment. IDH 1/2 mutation, 1p/19q co-deletion, MGMT methylation were found in 93, 50.8 and 65.3% of patients. Median follow-up was 98.3 months. In univariate analysis, overall survival was influenced by extent of resection (p = 0.011), IDH mutation (p < 0.001), 1p/19q co-deletion (p = 0.015) and MGMT methylation (p = 0.013). In multivariate analysis, RTOG clinical risk (p = 0.006), IDH mutation (p < 0.001) and 1p/19q co-deletion (p = 0.035) correlated with overall survival. RTOG clinical risk (p = 0.006), IDH mutation (p < 0.001) and lp/19q co-deletion (p = 0.035) correlated with overall survival. Conclusion: Both clinical and molecular factors are essential to determine prognosis and treatment strategies.

The role of clinical and molecular factors in low-grade gliomas: What is their impact on survival? / Franceschi, E.; Mura, A.; De Biase, D.; Tallini, G.; Pession, A.; Foschini, M. P.; Danieli, D.; Pizzolitto, S.; Zunarelli, E.; Lanza, G.; Bartolini, D.; Silini, E. M.; Visani, M.; Di Oto, E.; Tosoni, A.; Minichillo, S.; Lamberti, G.; Lanese, A.; Paccapelo, A.; Bartolini, S.; Brandes, A. A.. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 14:16(2018), pp. 1559-1567. [10.2217/fon-2017-0634]

The role of clinical and molecular factors in low-grade gliomas: What is their impact on survival?

Silini E. M.;
2018-01-01

Abstract

Aim: To evaluate relevance of clinical and molecular factors in adult low-grade gliomas (LGG) and to correlate with survival. Methods: We reviewed records from adult LGG patients from 1991 to 2015 who received surgery and had sufficient tissue to molecular biomarkers characterization. Results: 213 consecutive LGG patients were included: 17.4% were low-risk, according to Radiation Therapy Oncology Group (RTOG) risk assessment. IDH 1/2 mutation, 1p/19q co-deletion, MGMT methylation were found in 93, 50.8 and 65.3% of patients. Median follow-up was 98.3 months. In univariate analysis, overall survival was influenced by extent of resection (p = 0.011), IDH mutation (p < 0.001), 1p/19q co-deletion (p = 0.015) and MGMT methylation (p = 0.013). In multivariate analysis, RTOG clinical risk (p = 0.006), IDH mutation (p < 0.001) and 1p/19q co-deletion (p = 0.035) correlated with overall survival. RTOG clinical risk (p = 0.006), IDH mutation (p < 0.001) and lp/19q co-deletion (p = 0.035) correlated with overall survival. Conclusion: Both clinical and molecular factors are essential to determine prognosis and treatment strategies.
2018
The role of clinical and molecular factors in low-grade gliomas: What is their impact on survival? / Franceschi, E.; Mura, A.; De Biase, D.; Tallini, G.; Pession, A.; Foschini, M. P.; Danieli, D.; Pizzolitto, S.; Zunarelli, E.; Lanza, G.; Bartolini, D.; Silini, E. M.; Visani, M.; Di Oto, E.; Tosoni, A.; Minichillo, S.; Lamberti, G.; Lanese, A.; Paccapelo, A.; Bartolini, S.; Brandes, A. A.. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 14:16(2018), pp. 1559-1567. [10.2217/fon-2017-0634]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2867247
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 16
social impact